C80
Conditions
Interventions
Group 1: Therapy with 25mg rofecoxib per day, 45mg pioglitazone per day and 1,0g capecitabine bid per os
Group 2: Therapy with 25mg rofecoxib per day, 45mg pioglitazone per day and 50mg trofosfamide p
Sponsors
Abteilung für Hämatologie und Internistische Onkologie
Klinikum der Universität Regensburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with either gastrointestinal cancer, including pancreatic, and gall bladder cancer or urological cancer (group A) or metastatic melanoma, sarcoma, pulmonary and gynecological carcinoma or hematological malignancy (group B) were included in the. Additional eligibility criteria included: adequate baseline organ function as evidenced by a serum creatinine concentration at or below 1.8mg/dl, GOT, GPT and GGT below 1.25 times the normal concentration, white blood cell count over 2.0 cells per nL and a platelet count over 100000 cells per µL. Written informed consent had to be obtained before inclusion in the study.
Exclusion criteria
Exclusion criteria: Patients with significant comorbidity including acute infections, inadequately controlled diabetes mellitus, congestive heart failure, angina pectoris and cardiac arrhythmia requiring medical therapy were excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome / Outcome Measures (of the present secondary analysis):Assessment of renal function during and after end of treatment. Serum creatinine concentrations were measured before treatment and monthly during the treatment phase up to 6 months after end of treatment. Glomerular filtration rate was estimated using the method of Cockcroft and Gault. | — |
Countries
Germany
Contacts
Public ContactAlbrecht Reichle
Abteilung für Hämatologie und Internistische Onkologie Klinikum der Universität Regensburg
Outcome results
None listed